Entegris to expand three life sciences manufacturing facilities

The expanded capacity and capabilities include the development of a dedicated Life Sciences Technology Center

The facilities will develop and manufacture bioprocessing assemblies, such as the company's Aramus critical fluid handling product line currently used to produce and deliver vaccines worldwide.

Entegris has also started the development of its Life Sciences Technology Center located at its headquarters in Billerica, MA, which will provide application testing, process development, and solution demonstration services for bioprocess technologies including freeze, thaw, and filtration applications.

The announced expansions come as the pharmaceutical sector increases demand for high-purity systems designed for freezing, transporting, storing, and thawing drug substances, not just for COVID-19 vaccines, but also for oher treatments and therapeutics.

Bertrand Loy, Entegris’ President and CEO said the investment "further demonstrates the company's commitment to effectively serving this industry – now and in the future".

Better known for its operations in advanced materials science, Entegris considered itself a natural partner to the life sciences industry due to its expertise in complex manufacturing processes with their rigorous requirements for achieving high purity and high yields.

The company began developing solutions specific to bioprocessing needs before the COVID-19 pandemic.

More recently, it has used its capabilities in advanced manufacturing environments to provide key support to biopharmaceutical companies developing, producing and distributing vaccines.